Boston Scientific stock faces fresh recall and growth scrutiny
Published on 11/14/2026 at 10:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth and quality risks dominate
- Zacks named Boston Scientific its Bear of the Day on November 13 after further earnings-estimate reductions.
- Simply Wall St highlighted voluntary Class II recalls and execution risks across neuromodulation and interventional products.
- The WATCHMAN FLX Pro trial offers a clinical support point for a franchise facing weaker momentum.
Boston Scientific faced a new round of investor scrutiny on Friday, November 13, after Zacks Equity Research named the medical-device maker its Bear of the Day. The analysis pointed to further reductions in consensus earnings estimates after the company's third-quarter results and weaker expectations for 2027.
Zacks Equity Research said on November 13 that its consensus EPS estimate for the current year had fallen from 3.29 US dollars to 3.17 US dollars over the previous two months. Its estimate for the following year had declined from 3.39 US dollars to 3.09 US dollars. The analysis also described the shares as trading at about 15 times earnings, while projected growth was weakening.
Recall risks raise execution pressure
On November 13, Simply Wall St highlighted a cluster of voluntary Class II recalls from 2026. The analysis cited firmware issues in a neuromodulation therapy disc and manufacturing defects in Direxion Torqueable Microcatheters distributed in the United States and international markets.
For investors, the recalls add a quality and supply-chain risk to an existing growth debate. Simply Wall St also pointed to softer momentum in electrophysiology and WATCHMAN, while noting that the broader cardiovascular and MedSurg portfolio, restructuring savings and the planned Penumbra acquisition remain potential supports.
WATCHMAN remains a potential support
The WATCHMAN FLX Pro franchise retains a clinical argument after results from the SIMPLAAFY study. Simply Wall St said aspirin alone or reduced-dose NOAC regimens met the six-month noninferiority standard against dual antiplatelet therapy, with similar ischemic stroke rates and less bleeding. The findings could support adoption, but they do not remove the operating risks surrounding recalls, competition and integration.
Boston Scientific stock traded at 40.20 euros on Lang & Schwarz at 10:36 CET on Saturday, November 14.
Boston Scientific at a glance
- Company: Boston Scientific Corporation
- ISIN: US1011371077
- NYSE ticker: BSX
- Lang & Schwarz quote: 40.20 euros at 10:36 CET on November 14, 2026
US healthcare shares remain sensitive to earnings revisions, product quality and regulatory developments. Current market reports provide the broader market context.
